Report Store Get Proposal

AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

Download

Share

Home Blog Notizia 55

AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

Nov 03, 2017

Table of Contents

AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer

The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).

Tocagen’s combo therapy enters directly into phase 3 trials after getting approval from FDA

Tocagen is moving directly into a phase 3 trial with its combo therapy Toca 511 and Toca FC gene therapy in cancer and thus needs more patients. To facilitate the process FDA has provided a $2 million orphan drug grant payable over four years.

FDA warns companies marketing unverified products, derived from marijuana, claiming cancer treatment or cure

Under the U.S. Food and Drug Administration’s ongoing efforts to protect consumers from health fraud. The agency has recently issued warning letters to four companies. Action is taken against the companies illegally selling marijuana products online claiming to prevent, diagnose, treat, or cure cancer without any evidence to support the same.

FDA about to Revoke Claims regarding Heart Health benefits of Soy

In a recent statement Susan Mayne, director of the Center for Food Safety and Applied Nutrition at the FDA has said that, the relationship between soy protein and heart health does not meet the rigorous standard for an FDA-authorized health claim.

Downloads

Click Here To Get the Article in PDF

Recent Articles

DelveInsight- Business Consultant and Knowledge Partner

AUCATZYL Approved for R/R B-ALL; FDA Accepts NDA for Unicycive’s Oxylanthanum Carbonate; AstraZen...

Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease; GSK Announces Positive ...

CereVasc’s eShunt System Study; FDA Approves NGS-Based CDx for Trastuzumab Deruxtecan; Nanopath S...

Alcon’s 510(k) Clearance From the FDA; Globus Medical Received FDA Clearance; UK Pioneers F...

Downloads

Article in PDF

Recent Articles

Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune

GSK Receives FDA Fast Track Designation for Bepirovirsen; Gilead to Acquire CymaBay Therapeutics;...

Liquid Biopsy: Revolutionary Technique for Cancer Diagnosis

Nav1.7 Blockers- New Genre of Pain Relief Therapy

Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome’s Buyout; Abbott’s MitraClip4 ...

pharma-news-for-roche-astrazeneca-replimune

Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves Genentech’s GAZYVA for Lupus Nephritis; Glaukos’ EPIOXA Wins FDA Approval for Keratoconus Treatment; FDA Accepts Replimune’s RP1 BLA Resubmission for Advanced Melanoma; Cogent’s Bezuclastinib Earns FDA Breakthrough Therapy for SM-AHN; Amgen’s TEZSPIRE Gets FDA Nod for Chronic Rhinosinusitis with Nasal Polyps

Artificial Intelligence in Remote Patient Monitoring: Enabling Continuous, Predictive, and Personalized Care

Articles

Artificial Intelligence in Remote Patient Monitoring: Enabling Continuous, Predictive, and Personalized Care

pharma-news-for-boehringer-denali-regeneron

Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves Boehringer’s JASCAYD as First New IPF Therapy in Over a Decade; Denali Therapeutics’ Tividenofusp Alfa BLA Review for Hunter Syndrome Extended by FDA; Bicara’s Ficerafusp Alfa Earns FDA Breakthrough Tag for 1L HPV-Negative Head & Neck Cancer; BeOne Medicines’ Sonrotoclax Granted FDA Breakthrough Designation for Cancer Treatment; FDA Clears LIBTAYO for Adjuvant Use in Cutaneous Squamous Cell Carcinoma

business research

Cancer Treatment

Early Lung Cancer

Market Research

orphan drug grant

unresectable non-small cell lung cancer

AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes

Nov 03, 2017

Table of Contents

AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer

The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).

Tocagen’s combo therapy enters directly into phase 3 trials after getting approval from FDA

Tocagen is moving directly into a phase 3 trial with its combo therapy Toca 511 and Toca FC gene therapy in cancer and thus needs more patients. To facilitate the process FDA has provided a $2 million orphan drug grant payable over four years.

FDA warns companies marketing unverified products, derived from marijuana, claiming cancer treatment or cure

Under the U.S. Food and Drug Administration’s ongoing efforts to protect consumers from health fraud. The agency has recently issued warning letters to four companies. Action is taken against the companies illegally selling marijuana products online claiming to prevent, diagnose, treat, or cure cancer without any evidence to support the same.

FDA about to Revoke Claims regarding Heart Health benefits of Soy

In a recent statement Susan Mayne, director of the Center for Food Safety and Applied Nutrition at the FDA has said that, the relationship between soy protein and heart health does not meet the rigorous standard for an FDA-authorized health claim.